Evolve Private Wealth LLC Acquires Shares of 9,819 Cencora, Inc. $COR

Evolve Private Wealth LLC acquired a new stake in Cencora, Inc. (NYSE:COR) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 9,819 shares of the company’s stock, valued at approximately $3,316,000.

Several other hedge funds also recently modified their holdings of COR. United Bank boosted its position in shares of Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after buying an additional 305 shares during the last quarter. Nebula Research & Development LLC purchased a new position in shares of Cencora during the second quarter valued at approximately $595,000. Treasurer of the State of North Carolina boosted its position in shares of Cencora by 7.9% during the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock valued at $25,647,000 after buying an additional 6,244 shares during the last quarter. Diversify Advisory Services LLC boosted its position in shares of Cencora by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock valued at $747,000 after buying an additional 1,253 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its position in shares of Cencora by 26.0% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock valued at $22,025,000 after buying an additional 15,154 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of Cencora stock opened at $277.10 on Thursday. The business’s fifty day simple moving average is $286.62 and its 200 day simple moving average is $325.41. The firm has a market capitalization of $53.91 billion, a P/E ratio of 21.25, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The business had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, analysts anticipate that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora announced that its board has initiated a share buyback program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio (DPR) is 18.40%.

Analyst Ratings Changes

COR has been the topic of several analyst reports. Wells Fargo & Company cut their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. UBS Group lifted their target price on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley set a $342.00 target price on Cencora in a research report on Friday, May 8th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, Robert W. Baird cut their target price on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.